Multivalent anti-SARS-CoV-2 nanobodies
Provided herein are asymmetric biparatopic neutralizing nanobody-based antibodies which engage SARS-2 spike in at least two independent epitopes. Several biparatopic constructs showed synergy in neutralizing viral infection of cells. Data also showed that single biparatopic constructs are more effective than the combination of the parental monotopic constructs were at neutralization. The nanobodies that were identified in an initial screen of a large and highly diverse library bind to a single epitope that overlaps with the ACE2 binding site.
1. A construct, comprising a first binding domain, wherein the first binding domain is selected from the group consisting of:
a first polypeptide comprising first, second, and third complementarity determining regions corresponding to SEQ ID NOs: 2, 6, and 10, respectively;
a second polypeptide comprising first, second, and third complementarity determining regions corresponding to SEQ ID NOs: 3, 7, and 11, respectively; or
a third polypeptide comprising first, second, and third complementarity determining regions corresponding to SEQ ID NOs: 4, 8, and 12, respectively; wherein the first binding comprises a portion of an antibody including a heavy chain portion and having a binding domain that binds to a coronavirus.
2. The construct of claim 1 , further comprising a second binding domain, wherein the first and second binding domain are different and wherein the second binding domain comprises a portion of an antibody including a heavy chain portion and having a binding domain that binds to a coronavirus.
3. The construct of claim 2 , wherein the second binding domain comprises:
a first complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 1;
a second complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 5; and
a third complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 9.
4. The construct of claim 2 , wherein the first and second binding domains each further comprise:
a first framework region attached to an N-terminus of the first complementarity determining region;
a second framework region disposed between the first and second complementarity determining regions;
a third framework region disposed between the second and third complementarity determining regions; and
a fourth framework region attached to a C-terminus of the third complementarity determining region.
5. The construct of claim 1 , wherein the first binding domain is a polypeptide sequence corresponding to any one of SEQ ID NOs: 14-16.
6. The construct of claim 1 , wherein the first binding domain comprises a polypeptide sequence corresponding to any one of SEQ ID NOs: 180-186, wherein CDR1 comprises the first complementarity determining region, wherein CDR2 comprises the second complementarity determining region, and wherein CDR3 comprises the third complementarity determining region.
7. The construct of claim 2 , wherein the first binding domain is a polypeptide sequence corresponding to any one of SEQ ID NOs: 14 to 16 and the second binding domain is a polypeptide sequence corresponding to SEQ ID NO: 13.
8. The construct of claim 2 , wherein the first binding domain binds to a spike protein of a coronavirus or a receptor-binding domain of a coronavirus and the second binding domain binds to a spike protein of a coronavirus or a receptor-binding domain of a coronavirus.
9. The construct of claim 8 , wherein the coronavirus is SARS-CoV-2.
10. The construct of claim 9 , wherein the coronavirus is SARS-CoV-2 Delta variant.
11. The construct of claim 2 , wherein the second binding domain binds to a different epitope on a coronavirus than the first binding domain.
12. The construct of claim 2 , wherein the first binding domain binds to a first epitope of a target antigen, and the second binding domain binds to a second non-overlapping epitope of the target antigen.
13. The construct of claim 12 , wherein the target antigen is a coronavirus.
14. The construct of claim 2 , wherein one of the first or second binding domains overlaps an ACE2 binding site of SARS-CoV-2 and the other of the first or second binding domains does not overlap the ACE2 binding site of the SARS-CoV-2.
15. A biparatopic construct, wherein the construct comprises a first and second binding domain which each comprise a portion of an antibody including a heavy chain portion and having a binding domain that binds to a coronavirus, comprising:
the first binding domain, the second binding domain, and an Fc domain and hinge region of human IgG1 protein, the first binding domain and second binding domain coupled to the hinge region of the Fc domain; and
the first binding domain configured to bind to a first epitope on a coronavirus antigen, and the second binding domain configured to bind to a second epitope on the coronavirus antigen, wherein the first and second epitopes are non-overlapping;
wherein the second binding domain is:
a first complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 1;
a second complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 5; and
a third complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 9.
16. The construct of claim 15 , wherein the first binding domain comprises a first framework region coupled to a first complementarity determining region, a second framework region coupled to the first complementarity determining region and a second complementarity determining region, a third framework region coupled to the second complementarity determining region and a third complementarity determining region, and a fourth framework region coupled to the third complementarity determining region;
wherein the first binding domain is selected from the group consisting of:
a first polypeptide comprising first, second, and third complementarity determining regions that correspond to SEQ ID NOs: 2, 6, and 10, respectively;
a second polypeptide comprising first, second, and third complementarity determining regions that correspond to SEQ ID NOs: 3, 7, and 11, respectively; or
a third polypeptide comprising first, second, and third complementarity determining regions that correspond to SEQ ID NOs: 4, 8, and 12, respectively.
17. The construct of claim 16 , wherein the first binding domain comprises a polypeptide sequence having at least 90% sequence identity to any one of SEQ ID NOs: 14-16.
18. The construct of claim 16 , wherein the second binding domain comprises a polypeptide sequence corresponding to SEQ ID NO: 13 and is different than the first binding domain.
19. A construct, comprising a first binding domain, wherein the first binding domain is selected from the group consisting of:
a first polypeptide comprising first, second, and third complementarity determining regions corresponding to SEQ ID NOs: 2, 6, and 11, respectively; or
a second polypeptide comprising first, second, and third complementarity determining regions corresponding to SEQ ID NOs: 3, 7, and 12, respectively; wherein the first binding domain comprises a portion of an antibody including a heavy chain portion and having a binding domain that binds to a coronavirus.
20. The construct of claim 19 , wherein a second binding domain comprises:
a first complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 1;
a second complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 5; and
a third complementarity determining region comprising a polypeptide sequence corresponding to SEQ ID NO: 9 and wherein the second binding domain comprises a portion of an antibody including a heavy chain portion and having a binding domain that binds to a coronavirus.